Pacira BioSciences (PCRX)
Develops non-opioid pain and musculoskeletal treatments built on a liposome drug-delivery platform.
Something off on this page? Send us feedback.
Sells non-opioid pain-management and musculoskeletal-health products to hospitals and outpatient surgery centers, led by EXPAREL, a long-acting local anesthetic built on an inherited liposome delivery technology. Revenue concentrates heavily in that single product, distributed through a small number of pharmaceutical wholesalers.
Develops non-opioid treatments for postsurgical pain and musculoskeletal conditions, sold mainly to hospitals and outpatient surgical centers rather than directly to patients. EXPAREL, a long-acting local anesthetic built on an inherited liposome drug-delivery technology, accounts for most revenue; ZILRETTA, an extended-release knee osteoarthritis injection, and iovera°, a cryoanalgesia device agreed for sale to another medical company, round out the portfolio.
Assembled through acquisition rather than built around a single founder, the business later added knee osteoarthritis and gene-therapy research. A recently enacted federal reimbursement rule now gives its non-opioid products separate payment status in outpatient settings.
Three national pharmaceutical wholesalers handle the large majority of distribution. Patent litigation over the lead product settled on terms deferring broad generic competition toward the end of the decade, while a gene-therapy candidate anchors the push beyond the founding product line.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 9, 2026 | Leerink Partners | Target | Target: — | Target: $28 |
| Aug 17, 2026 | Truist Financial | Target | Target: $25 | Target: $30 |
| Aug 5, 2026 | RBC Capital | Reiterate | Rating: —Target: — | Target: $25 |
| May 1, 2026 | Needham | Reiterate | Rating: —Target: $63 | Target: $32 |
| Dec 8, 2025 | Barclays | Target | Target: $24 | Target: $27 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $251.0M · Total debt $412.1M · Total assets $1.24B · Shareholders' equity $672.0M
- Revenue
- $192.4M
- Operating income
- $4.3M
- Net income
- $4.7M
No dividends on record.
| Institutions | 111.51% | 44.45M shares | |
|---|---|---|---|
| 257 holders · as of Jun 30, 2026 | |||
| Insiders | 11.41% | 4.55M shares | |
| 17 holders · as of Aug 18, 2026 | |||
| Strategic holders | 10.55% | 4.21M shares | |
| 1 holder · as of Feb 14, 2022 | |||
| Adds to | 133.47% | ||
39.86M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 133.47%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 16.82% | 6.71M | as of Jun 30, 2026 |
Macquarie Group LimitedStrategic | 10.55% | 4.21M | filed Feb 14, 2022 |
Pedro EscuderoInsider | 7.37% | 2.94M | filed Mar 12, 2026 |
Doma Perpetual Capital Management LLCInstitution | 6.97% | 2.78M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 6.04% | 2.41M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 17, 2026 | Jonathan Slonin | officer: Chief Medical Officer | −3,040 | $23.23 |
| Jun 11, 2026 | Lauren Riker | officer: Senior Vice President, Finance | −6,115 | $23.50 |
| Jun 4, 2026 | Kristen Williams | officer: Chief Administrative Officer | −10,259 | $22.27 |
| Apr 23, 2026 | Shawn Cross | officer: Chief Financial Officer | −12,941 | $25.16 |
| Apr 20, 2026 | Shawn Cross | officer: Chief Financial Officer | −7,714 | $25.14 |
- Heron Therapeutics
Specialty biopharma in non-opioid postsurgical pain and antiemetic care
- Vertex Pharmaceuticals
Cystic fibrosis leader diversifying into non-opioid acute pain treatment
- Bioventus
Durham, NC medical device maker of hyaluronic acid knee OA injectables
- Anika Therapeutics
Hyaluronic acid viscosupplements rivaling non-opioid OA knee injectables
- Sanofi (ADR)
Global pharma marketing Synvisc-One, an HA rival to intra-articular OA therapy
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Pacira BioSciences | $24.64 | +2.20% | $948.4M | 68.6 | 7.9 | 1.3 | +6.2% |
| Heron Therapeutics | $0.2846 | +5.41% | $51.1M | — | — | 0.3 | +1.3% |
| Vertex Pharmaceuticals | $515.01 | +0.84% | $129.62B | 29.7 | 26.8 | 10.3 | +12.5% |
| Bioventus | $13.50 | +1.43% | $901.7M | 17.3 | 17.0 | 1.5 | +3.8% |
| Anika Therapeutics | $20.90 | +0.97% | $277.0M | — | 23.5 | 2.3 | +15.6% |
| Sanofi (ADR) | $42.25 | −0.59% | $102.05B | 75.6 | — | 1.8 | +11.2% |
| Median | 29.7 | 23.5 | 1.8 | +11.2% |